Br J Ophthalmol. 2010 May;94(5):532-5. Epub 2009 Sep 23. Topical chemotherapy for ocular surface squamous neoplasia: current status. Sepulveda R, Pe'er J, Midena E, Seregard S, Dua HS, Singh AD. SourceDepartment of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Abstract Although there are no randomised trials directly comparing topical chemotherapeutic agents mitomycin-C, 5-fluorouracil, and interferon-alpha2b, published studies indicate equal efficacy of these agents for treatment of non-invasive ocular surface squamous neoplasia (80%-88%). 5-Fluorouracil may be preferred, given low incidence of serious side effects and low cost to the patient. PMID: 19776089 [PubMed - indexed for MEDLINE]
Topical chemotherapy for ocular surface squamous neoplasia: current status.
MIDENA, EDOARDO;
2010
Abstract
Br J Ophthalmol. 2010 May;94(5):532-5. Epub 2009 Sep 23. Topical chemotherapy for ocular surface squamous neoplasia: current status. Sepulveda R, Pe'er J, Midena E, Seregard S, Dua HS, Singh AD. SourceDepartment of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Abstract Although there are no randomised trials directly comparing topical chemotherapeutic agents mitomycin-C, 5-fluorouracil, and interferon-alpha2b, published studies indicate equal efficacy of these agents for treatment of non-invasive ocular surface squamous neoplasia (80%-88%). 5-Fluorouracil may be preferred, given low incidence of serious side effects and low cost to the patient. PMID: 19776089 [PubMed - indexed for MEDLINE]
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
